妊娠中の吐き気と不快な妊娠結果との関連: nuMoM2b研究の結果
Ya-Ling Hsieh1, Chia-Jung Chiang2, Tsung Yu3
1Nursing Department, Chi Mei Medical Center, Tainan, Taiwan.
Archives of gynecology and obstetrics
|September 3, 2025
まとめ
妊娠中の吐き気 (NVP) は結果に限られた影響を及ぼしますが,不十分な妊娠体重増加 (GWG) は妊娠中の不良結果の主な危険因子です. 中度から重度のNVPを持つ妊婦には栄養補助が不可欠です.
科学分野:
- 産婦人科
- 妊婦と胎児の医療
- 生殖 健康
背景:
- 妊娠中の吐き気 (NVP),妊娠中症 (HG) を含め,生理周期のアウトカムと関連付けられていますが,結果は矛盾しています.
- NVPの重症度と妊娠の結果の関係を理解することは,臨床管理にとって極めて重要です.
研究 の 目的:
- NVPの重症度と不良妊娠結果との関連を調べる
- これらの関係における妊娠体重増加 (GWG) の潜在的な仲介的役割を評価する.
主な方法:
- 米国のnuMoM2bコホートにおける8396人の女性から得られたデータを分析した.
- NVPの重症度は,PUQEスコアを用いて評価された.
- 産後アウトカムには,出生体重,妊娠年齢,早産,SGA,およびLBWが含まれていました. GWGの適度性は,医学研究所のガイドラインに従って評価されました.
主要な成果:
- 中等から重度のNVPの1回の訪問は,出生体重 (−41. 4g) の控えめな減少と関連していました.
- NVPの状態に関係なく,不十分なGWGは妊娠期間短縮,出生体重減少,早産,LBW,SGAのリスク増加と関連していました.
結論:
- NVPの重症度だけでは,短期的な妊娠結果に限られた影響を及ぼしました.
- 不十分なGWGは,妊娠の不良な結果のための重要な変更可能な危険因子です.
- 栄養補助と症状管理は,妊婦,特に中度から重度のNVP患者にとって重要です.
関連する概念動画
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Pathophysiology of Vomiting
1.1K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
1.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
439
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
366
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
366
Mitral Valve Prolapse III: Nursing Management
35
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
35


